Serum 2′-5′-Oligoadenylate Synthetase Levels and Clinical Response to Interferon-β Therapy in Women with Genital Human Papillomavirus Infection

• Published in: The Journal of infectious diseases Vol. 169; no. 5; pp. 1112 - 1115
• Main Authors: Rusconi, Stefano, Agarossi, Alberto, Ravasi, Luisa, Tonts, Aldo, Conti, Mario, Galli, Massimo
• Format: Journal Article
• Language: English
• Published: United States The University of Chicago Press 01.05.1994; University of Chicago Press
• Subjects: 2',5'-Oligoadenylate Synthetase - blood; Adult; AIDS; Animals; Biopsies; Concise Communications; Condylomata Acuminata - enzymology; Condylomata Acuminata - therapy; Enzyme Induction; Epithelial cells; Female; Follow-Up Studies; Humans; In situ hybridization; Infections; Interferon-beta - therapeutic use; Macrophages; Middle Aged; Mucosa; Papillomaviridae - drug effects; T lymphocytes; Terminal illnesses
• ISSN: 0022-1899; 1537-6613
• DOI: 10.1093/infdis/169.5.1112

To investigate the activity of parenterally administered interferon-β (IFN-β) in women with genital human papillomavirus (HPV) infection, serum 2′-5′-oligoadenylate synthetase (2′-5′OAS), an enzyme induced by IFNs, was measured before, during, and after therapy. Serum levelsof 2′-5′OAS significantly increased during therapy (P = .005). The patients classifiedas not responding to treatment at 3 months of follow-up had baseline levels of 2′-5′OAS significantly higher than those who responded to treatment (P = .0011). Differences between the IFN-β treated group and untreated controls appeared at day6 (P = .0019). 2′-5′OAS is a useful parameter in monitoring parenterally administered IFN-β. The data suggest that women with genital HPV infection and elevated baseline levels of 2′-5′OAS are unlikely to respond to therapywith IFN-β.